Introduction and indications of Alpelisib (Alpelisib, Piqray)

Alpelisib (English nameAlpelisib, trade name Piqray) is a new type of targeted therapy drug developed and produced by Novartis Pharmaceuticals. In recent years, it has received widespread attention in the field of breast cancer treatment. It blocks the growth signals of cancer cells and inhibits tumor progression by precisely inhibiting the activity of PIK3CA enzyme. This unique mechanism of action targets the common PIK3CA mutation in breast cancer cells. This mutation is relatively common in advanced breast cancer and is one of the key factors leading to abnormal proliferation and survival of breast cancer cells.

The indications of Apelvis are: used in combination with fulvestrant to treat postmenopausal women and men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer whose disease has progressed despite endocrine therapy. This treatment option has been approved by the US FDA and has shown significant therapeutic effects in clinical trials.

However, before using Apelvis, patients need to undergo a complete physical examination to ensure that the drug is suitable for their condition. At the same time, during the treatment process, patients should pay close attention to their physical condition, and if they have any discomfort or side effects, they should promptly inform their doctor and seek help.

Apelix is administered orally, usually once daily, and the dosage needs to be determined by the doctor based on the patient's specific condition. Patients must strictly follow their doctor's instructions when using Apelvis to ensure the effectiveness and safety of the drug.

Although Apelvis has shown remarkable results in the treatment of breast cancer, it should be noted that the drug is not yet commercially available in China. For patients in need of medicines, please purchase them from overseas regular channels. Currently, a box of the Indian version of the original medicine costs about 5,000 yuan, while the Laos version is cheaper. Each box of the same specifications sells for about 2,500 yuan. Please choose according to your own situation.

In short, apelvis, as a new breast cancer treatment drug, provides a new treatment option for patients with advanced breast cancer. Its unique pharmacological mechanism and significant therapeutic effect bring new hope to breast cancer patients.